LMAT is the ticker symbol for LEMAITRE VASCULAR INC, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks LMAT with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is LMAT a good stock to buy?

13F Pro's AI ranking engine scores LMAT at 66.1/100, ranked #433 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for LMAT is available at https://13fpro.ai/company/LMAT. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source LMAT data?

All LEMAITRE VASCULAR INC fundamentals and ownership data come directly from SEC EDGAR. LEMAITRE VASCULAR INC files with the SEC under CIK 1158895. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

LEMAITRE VASCULAR INC LMAT

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #433 of 2,925TOP 25%

Why it scores 66 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$70.38M

Quarter to Jun 30

Net income

$17.05M

Quarter to Jun 30

Free cash flow

$13.65M

Quarter to Jun 30

Operating margin

29.0%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$2.36B total

BlackRock, Inc.

$314.07M+4.1%

Conestoga Capital Advisors, LLC

$131.23M-7.4%

FIRST TRUST ADVISORS LP

$104.93M+9.6%

CONGRESS ASSET MANAGEMENT CO /MA

$92.48M+15.5%

VANGUARD CAPITAL MANAGEMENT LLC

$91.49M+4.5%

STATE STREET CORP

$86.50M+5.3%

Copeland Capital Management, LLC

$80.55M-3.6%

GEODE CAPITAL MANAGEMENT, LLC

$75.70M+19.8%

PRICE T ROWE ASSOCIATES INC /MD/

$72.47M+156.0%

VANGUARD PORTFOLIO MANAGEMENT LLC

$58.04M+7.5%

GENEVA CAPITAL MANAGEMENT LLC

$56.53M-21.9%

DIMENSIONAL FUND ADVISORS LP

$47.39M+3.7%

GOLDMAN SACHS GROUP INC

$45.41M+9.4%

Invesco Ltd.

$43.03M+34.3%

MORGAN STANLEY

$33.71M-13.3%

CAMDEN ASSET MANAGEMENT L P /CA

$33.33MNew

NORTHERN TRUST CORP

$31.99M+6.6%

TWO SIGMA INVESTMENTS, LP

$30.37M+12.3%

ROYAL BANK OF CANADA

$29.63M+13.2%

Annex Advisory Services, LLC

$23.82M-0.9%

UBS Group AG

$23.78M+498.3%

ENVESTNET ASSET MANAGEMENT INC

$23.48M-10.8%

KENNEDY CAPITAL MANAGEMENT LLC

$21.97M-3.3%

READYSTATE ASSET MANAGEMENT LP

$21.26M0.0%

KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC

$21.16M-4.4%

See all 344 institutional holders →

What's Driving LMAT's Business? Latest 10-Q Breakdown

15/15 datapoints verified

AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 10% YoY to $70.4M with gross margin up 210bps to 72.1%, as growth was broad-based across all three geographies led by grafts and shunts.

Biggest Revenue Drivers

Americas$43.5M+5% YoY

Increased sales of grafts, shunts, and patches, offset by decreased catheter sales

Europe, Middle East and Africa$22.1M+18% YoY

Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters

Biggest Revenue Drivers

Total revenue: $70.4M+10% YoY

Americas$43.5M+5% YoY

Increased sales of grafts, shunts, and patches, offset by decreased catheter sales

Europe, Middle East and Africa$22.1M+18% YoY

Increased sales of grafts, shunts, patches, and valvulotomes, offset by decreased catheters

Asia Pacific$4.8M+18% YoY

Increased sales of clips, grafts, and catheters

Largest Expense Items

Sales and marketing$14.4M-3% YoY

Lower compensation, commissions, and contest expenses

General and administrative$11.1M+7% YoY

Higher headcount and wage-driven compensation, and increased professional fees

Research and development$4.8M+37% YoY

Higher third-party service fees and supplies for the allograft tissue transfer to Burlington, plus new Billerica warehouse start-up costs

Margins: Gross margin rose 210bps to 72.1%, driven by sales price increases, favorable product mix, and lower shipping costs, partially offset by unfavorable manufacturing efficiencies and higher excess and obsolescence charges.

Watch Items from the Filing

FDA issued a warning letter after an April 2025 Artegraft facility inspection; a June 2026 re-inspection identified additional new observations, with remediation ongoing.
Biologics represented 55% of worldwide sales in Q2 2026, a significant concentration in a product category the company calls differentiated and growing.
Direct-to-hospital sales were 95% of total net sales in the quarter, reflecting the company's strategy of transitioning distributor markets to direct sales.
$172.5M of 2.50% convertible senior notes outstanding; conversion price adjusts downward each time the quarterly dividend exceeds $0.16/share, currently $0.25.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/LMAT

Earnings Per Share

13fpro.ai/company/LMAT

Loading ratio trend…

LEMAITRE VASCULAR INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$249.6M	$57.7M	27.2%
FY 2024	10-K	$219.9M	$44.0M	23.8%
FY 2023	10-K	$193.5M	$30.1M	19.0%
FY 2022	10-K	$161.7M	$20.6M	16.6%
FY 2021	10-K	$154.4M	$26.9M	23.6%
FY 2020	10-K	$129.4M	$21.2M	22.3%

About LEMAITRE VASCULAR INC (LMAT): stock profile, AI score and financials

LEMAITRE VASCULAR INC (LMAT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores LMAT at 66.1/100 on a composite quality score built from its SEC filings, placing it at rank #433 of 2,925 stocks — the top 25% of the AI-ranked universe. LMAT scores in the top quartile across profitability (87.9), balance sheet strength (86.8), free cash flow (82.2). Areas of concern include revenue scale (27.7) and institutional flow (34.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 30.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), LEMAITRE VASCULAR INC reports quarterly revenue of $70.4M, net income of $17.1M, an operating margin of 29.0%. LMAT trades on the Nasdaq exchange and files with the SEC under CIK 1158895. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LMAT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LEMAITRE VASCULAR INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1158895 →

LEMAITRE VASCULAR INC LMAT

Top Institutional Holders

What's Driving LMAT's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

LMAT key financials by period

LMAT insiders

About LEMAITRE VASCULAR INC (LMAT): stock profile, AI score and financials

LEMAITRE VASCULAR INC LMAT

Top Institutional Holders

What's Driving LMAT's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

LMAT key financials by period

Companies similar to LMAT

LMAT insiders

About LEMAITRE VASCULAR INC (LMAT): stock profile, AI score and financials